Weekly OHDSI Digest - 12Mar2018

MauraBeaton · March 12, 2018, 8:51pm

OHDSI MEETINGS THIS WEEK

OHDSI Community Call - Tuesday at 12pm ET (5pm CET)
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.98682213
US TOLL: +1-415-655-0001
Meeting Number: 199 982 907

Population-Level Estimation (Western hemisphere) workgroup meeting - Thursday at 12pm ET (5pm CET)
https://meetings.webex.com/collabs/#/meetings/detail?uuid=M3T9BZV9RSB6YNDM8WDDZMI19D-D1JL&rnd=229240.54296

Hadoop WG meeting - Friday at 11am ET (4pm CET)
https://meet.lync.com/quintiles-quintilesims/mui.vanzandt/R8V4N3S9
Call in Number: 1-646-838-2458
Attendee access code: 75630528

GIS working group meeting - Monday (March 19th) at 10am ET

Meeting Number: 735 317 239
Password: gaia

ANNOUNCEMENTS

Call for presenters for March 27th OHDSI call:
The deadline to submit abstracts for the AMIA 2018 Annual Symposium was March 8th. We’d love to get a sense of OHDSI’s presence at AMIA and are inviting collaborators who submitted an abstract to join our March 27th call and give us a brief overview of the work you submitted. If you’d like to let the community know what you’ll be presenting at AMIA, please let is know by replying to this thread: Who submitted an abstract for AMIA’s annual symposium?

2018 OHDSI F2F: Don’t forget to sign-up! Deadline is this Friday, March 16th! https://www.ohdsi.org/events/2018-ohdsi-face-to-face/
PLEASE NOTE: Seating for this event is very limited and completion of the sign-up form does not guarantee you a spot at the meeting. Registration requests can be submitted until March 16th, after that date each request will be reviewed by the OHDSI leadership team and an email confirming attendance will be sent to selected participants on March 23rd. Also, this is a working meeting. All in attendance are expected to participate in discussions and contribute their knowledge and skills to each session they attend.

2018 OHDSI Symposium - Collaborator showcase
Back by popular demand, the collaborator showcase will be part of the 2018 OHDSI Symposium, set to take place on September 18th at the Bethesda North Marriott! Once again we’ll be inviting collaborators to participate in the collaborator showcase by submitting abstracts to give poster presentations, software demonstrations or oral presentations. More details coming soon!

OHDSI China Hack-a-thon - SAVE THE DATE Mark your calendars! The OHDSI China Hack-a-thon is officially set to take place on May 18th – 20th in Shanghai. More details to be posted soon.

Every new beginning comes from some other beginning’s end.

Seneca

COMMUNITY PUBLICATIONS

Improving access to state of the art statistical methods for use in applied clinical research.

Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.

ncbi.nlm.nih.gov

Antiplatelet Therapy and Clinical Outcomes Following Myocardial Infarction Among Patients in a U.S. Employer-Based Insurance Database.

MD Patel, D Wu, MR Chase, P Mavros, K Heithoff, ME Hanson and RJ Simpson, Journal of managed care & specialty pharmacy, Jun 2017

Estimates of residual cardiovascular risks among patients who have experienced a recent acute myocardial infarction (MI) are predominantly derived from secondary prevention trial populations, patient registries, and population-based cohorts.To generate real-world evidence of antiplatelet treatment and recurrent events following MI in patients on antiplatelet treatment among commercial, employer-based insured patients in a large administrative database.This was a retrospective cohort claims database study using the Truven Health MarketScan Commercial Claims and Encounters and Medicare Supplemental databases between 2007-2011. Patients with an acute MI hospitalization with a discharge date between 2008 and 2010 were included. Excluded were those patients with documentation of stroke, transient ischemic attack (TIA), or severe bleeding at or before index hospitalization and with concomitant use of anticoagulant therapy following index hospitalization. Patients treated with clopidogrel following the index MI hospitalization were followed up to 1 year for repeat MI, stroke, and coronary revascularization.Among 33,943 post-MI continuous clopidogrel users without history of stroke, TIA, or bleeding, 22% had diabetes, whereas angina and renal impairment were less prevalent (5% and 7%, respectively). Over the 1-year follow-up, 2.4% experienced a repeat MI or stroke, and 8.2% underwent coronary revascularization. Angina, diabetes, and renal impairment were associated with elevated 1-year risk of repeat MI or stroke.This study suggests that there is residual cardiovascular risk, although relatively low, in an insured, secondary prevention population on antiplatelet treatment following an MI. In patients with MI, identifying angina, diabetes, and renal impairment may aid risk stratification and guide the effective management of these higher-risk patients.Funding for this research was provided by Merck & Co. Although Merck & Co. formally reviewed a penultimate draft, the opinions expressed are those of the authorship and may not necessarily reflect those of the company. Reed Chase, Wu, Mavros, Heithoff, and Hanson are employees of Merck Sharp & Dohme, a subsidiary of Merck & Co., and may own stock and/or hold stock options in the company. Patel was an employee of Merck & Co. during the conduct of this study and preparation of the manuscript. Simpson is a paid consultant for Merck, Pfizer, and Amgen and has received speaker's fees from Merck and Pfizer. Study concept and design were contributed by all authors except Hanson. Heifhoff and Patel collected the data, and data interpretation was performed by Simpson, Mavros, Patel, Wu, and Hanson. The manuscript was written by Hanson, Mavros, and Patel and revised by Heithoff, Wu, Simpson, and Reed Chase.